Nitin Kumar1, Fateh Bazerbachi2, Tarun Rustagi2, Thomas R McCarty3, Christopher C Thompson1, Manoel P Galvao Neto4, Natan Zundel5, Erik B Wilson6, Christopher J Gostout2, Barham K Abu Dayyeh7. 1. Department of Gastroenterology, Brigham and Women's Hospital, Boston, MA, USA. 2. Department of Gastroenterology, Mayo Clinic, Rochester, MN, USA. 3. Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA. 4. Gastro Obese Center, São Paulo, Brazil. 5. Department of Surgery, Florida International University, Miami, FL, USA. 6. Department of Surgery, University of Texas, Houston, TX, USA. 7. Department of Gastroenterology, Mayo Clinic, Rochester, MN, USA. AbuDayyeh.Barham@mayo.edu.
Abstract
BACKGROUND: The Orbera intragastric balloon (IGB) has been approved by the US Food and Drug Administration for use in patients with a body mass index (BMI) between 30 and 40 kg/m2 and is in wide use worldwide as a primary and bridge obesity management tool. The balloon filling volume (BFV) ranges between 400 and 700 mL of saline. Our objective was to determine whether there is an association between BFV and clinically relevant endpoints, namely weight loss outcomes, balloon tolerability, and adverse events. METHODS: A systematic review of studies investigating the use of the Orbera IGB system for obesity treatment was performed. Data was examined using random effects modelling and meta-regression analyses. RESULTS: Forty-four studies (n = 5549 patients) reported BFV and % total body weight loss (TBWL) at 6 months. Pooled %TBWL at 6 months was 13.2% [95% CI 12.3-14.0]. A funnel plot demonstrated a low risk of publication bias. Meta-regression showed no statistically significant association between filling volume and %TBWL at 6 months (p = 0.268). Higher BFV was associated with lower rates of esophagitis (slope = -0.008, p < 0.001) and prosthesis migration (slope = -0.015, p < 0.001). There was no association between BFV and early removal (p = 0.1), gastroesophageal reflux symptom (p = 0.64), or ulcer rates (p = 0.09). CONCLUSIONS: No association was observed between Orbera IGB filling volume and weight loss outcomes. Higher volumes appear to be associated with lower migration and esophagitis rates; thus, a balloon filling volume of 600-650 mL is recommended.
BACKGROUND: The Orbera intragastric balloon (IGB) has been approved by the US Food and Drug Administration for use in patients with a body mass index (BMI) between 30 and 40 kg/m2 and is in wide use worldwide as a primary and bridge obesity management tool. The balloon filling volume (BFV) ranges between 400 and 700 mL of saline. Our objective was to determine whether there is an association between BFV and clinically relevant endpoints, namely weight loss outcomes, balloon tolerability, and adverse events. METHODS: A systematic review of studies investigating the use of the Orbera IGB system for obesity treatment was performed. Data was examined using random effects modelling and meta-regression analyses. RESULTS: Forty-four studies (n = 5549 patients) reported BFV and % total body weight loss (TBWL) at 6 months. Pooled %TBWL at 6 months was 13.2% [95% CI 12.3-14.0]. A funnel plot demonstrated a low risk of publication bias. Meta-regression showed no statistically significant association between filling volume and %TBWL at 6 months (p = 0.268). Higher BFV was associated with lower rates of esophagitis (slope = -0.008, p < 0.001) and prosthesis migration (slope = -0.015, p < 0.001). There was no association between BFV and early removal (p = 0.1), gastroesophageal reflux symptom (p = 0.64), or ulcer rates (p = 0.09). CONCLUSIONS: No association was observed between Orbera IGB filling volume and weight loss outcomes. Higher volumes appear to be associated with lower migration and esophagitis rates; thus, a balloon filling volume of 600-650 mL is recommended.
Authors: Gregory G Ginsberg; Bipan Chand; Gregory A Cote; Ramsey M Dallal; Steven A Edmundowicz; Ninh T Nguyen; Aurora Pryor; Christopher C Thompson Journal: Gastrointest Endosc Date: 2011-11 Impact factor: 9.427
Authors: A Genco; M Cipriano; V Bacci; M Cuzzolaro; A Materia; L Raparelli; C Docimo; M Lorenzo; N Basso Journal: Int J Obes (Lond) Date: 2006-01 Impact factor: 5.095
Authors: Iñaki Imaz; Carmen Martínez-Cervell; Elvira Elena García-Alvarez; Juan Manuel Sendra-Gutiérrez; Jesús González-Enríquez Journal: Obes Surg Date: 2008-05-06 Impact factor: 4.129
Authors: Barham K Abu Dayyeh; Nitin Kumar; Steven A Edmundowicz; Sreenivasa Jonnalagadda; Michael Larsen; Shelby Sullivan; Christopher C Thompson; Subhas Banerjee Journal: Gastrointest Endosc Date: 2015-07-29 Impact factor: 9.427
Authors: Maciej Patrzyk; Jenny Sonke; Anne Glitsch; Rebecca Kessler; Antje Steveling; Sebastian Lünse; Lars Ivo Partecke; Claus-Dieter Heidecke; Wolfram Kessler Journal: Visc Med Date: 2021-02-17
Authors: Levan Tsamalaidze; John A Stauffer; Lisa C Arasi; Diego E Villacreses; Jose Salvador Serrano Franco; Steven Bowers; Enrique F Elli Journal: Obes Surg Date: 2018-02 Impact factor: 4.129
Authors: Fateh Bazerbachi; Eric J Vargas; Monika Rizk; Daniel B Maselli; Taofic Mounajjed; Sudhakar K Venkatesh; Kymberly D Watt; John D Port; Rita Basu; Andres Acosta; Ibrahim Hanouneh; Naveen Gara; Meera Shah; Manpreet Mundi; Matthew Clark; Karen Grothe; Andrew C Storm; Michael J Levy; Barham K Abu Dayyeh Journal: Clin Gastroenterol Hepatol Date: 2020-04-30 Impact factor: 11.382
Authors: Saud Al-Subaie; Hamad Al-Barjas; Salman Al-Sabah; Saud Al-Helal; Ashraf Alfakharani; Salah Termos Journal: Int J Surg Case Rep Date: 2017-11-08